Background: Obesity is associated with hyperparathyroidism and increased bone mass and turnover, but their pathogeneses are unclear.
the most plausible mechanism. An essential component of the mechanostat is considered to be the network of canaliculi and osteocytes that pervades bone (9) . Mechanical loading studies in animals indicate that stimulated new bone formation is accompanied by down-regulation of sclerostin in osteocytes resulting in disinhibition of the WNT signaling pathway, a major regulator of bone mass and bone mass accrual (10, 11) .
Fat tissue functions as an endocrine organ that links nutrition to other body systems (12) . Thus, the relationship between fat mass and bone mass may also reside in one of the adipokines secreted by fat tissue. Leptin is a likely candidate because its serum concentration closely mirrors fat mass (13) . Serum leptin has been shown to relate positively to bone mineral density in a number of studies (14 -18) . However, in some studies when serum leptin concentrations are corrected for body weight, leptin relates negatively to bone mineral density (19, 20) . Evidence of abundant functional leptin receptors in osteoblasts supports a role for leptin in bone formation (21, 22) . Furthermore, several animal studies have demonstrated effects of leptin administration on bone. Leptin-deficient ob/ob mice administered leptin ip had increased bone mineral density, bone mineral content, and femoral length (23) and decreased bone fragility (24) . In ovariectomized rats, continuous sc leptin administration attenuated cancellous bone loss (25) . These effects on bone suggest that leptin may act in concert with the hormones responsible for mineral homeostasis and metabolism, namely PTH, 1,25-dihydroxyvitamin D (1,25D), and fibroblast growth factor 23 (FGF23). These hormones form an integrated system for regulating calcium and phosphate transport at the gut, bone, and kidney and are essential for mineral retention by the skeleton (26) .
Of the three mineral-regulating hormones, PTH is most consistently reported to be increased in obesity (27) (28) (29) (30) . Furthermore, serum PTH and body mass index (BMI) are positively related in samples of healthy subjects (31-34). We and others have shown serum PTH in obesity is independent of vitamin D status and does not represent, as is commonly assumed, secondary hyperparathyroidism from vitamin D insufficiency (30, 35) . Given as daily sc injections, PTH is strongly anabolic, causing increased bone turnover and increased bone mass in patients with osteoporosis (36). In a mouse model, PTH increases bone mass by down-regulating sclerostin production in osteocytes (37, 38). PTH also increases the activity of 1␣-hydroxylase, promoting production of renal 1,25D, the main regulator of active calcium absorption in the gut. In obesity, reported serum levels of 1,25D are inconsistent, with some studies finding increased levels (27, 28) and others decreased levels (39). On the other hand calcium absorption is positively related to 1,25D in obesity and decreases after weight loss induced by bariatric surgery (40). In obesity, serum concentrations of FGF23 have not been studied, although a recent publication reports that serum FGF23 relates positively with fat mass in elderly subjects (41). FGF23 is secreted by bone cells (42) and down-regulates renal 1,25D production and phosphate reabsorption (43, 44). It is a major bone hormone regulating phosphate homeostasis and vitamin D metabolism, although its influence in modulating bone mass remains to be established.
In a previous case control study in obesity, we speculated that the hyperparathyroidism and high bone turnover we observed in obesity may be directly related to serum leptin levels and that the serum PTH levels might link bone mass to fat mass by influencing secretion of sclerostin (30) . Thus, the aims of this study were to examine the effect of simple obesity on the relationships among the serum levels of leptin, PTH, 1,25D, and FGF23 and to investigate whether their effect on serum sclerostin might explain the influence of obesity on bone metabolism.
Subjects and Methods

Subjects
Subjects were 20 white women presenting to St. Vincent's Bariatric Surgery Center in Carmel, IN, for Roux-en-Y gastric bypass surgery for obesity between November 2005 and April 2007. Seven of the bariatric surgery subjects were postmenopausal, and of these, four were on sex steroid replacement therapy. These subjects were drawn randomly from an ongoing study to evaluate the effect of bariatric surgery on anthropomorphic, biochemical, and hormonal markers. All subjects provided informed consent for the study. Controls were 20 premenopausal women randomly selected from a database of healthy women who had previously consented and donated fasting blood samples to the Indiana Clinical Research Center for observational research between November 2005 and April 2007. They were matched to subjects for age, race, and date of blood draw.
Methods
Height was measured using a Harpenden stadiometer and weight measured using a ScaleTronix scale. Age was recorded at the time of blood collection. BMI was calculated as kilograms per square meter. Biochemistries were measured in serum that had been stored at Ϫ80 C. Leptin was measured by ELISA [within-assay coefficient of variation (CV) of 3.7%, between-assays CV of 4.0%; Millipore, St. Charles, MO). PTH was measured by a two-site immunoassay (CV of 9.7% at 17.5 pg/ml; Nichols Institute Diagnostics, San Juan Capistrano, CA). 25-Hydroxyvitamin D (25D) and 1,25D were measured by RIA (CV of 8.1 and 9.1%, respectively, DiaSorin, Stillwater, MN). FGF23 was measured by ELISA (CV of 4.4%; Kainos Laboratories, Inc., Tokyo, Japan). Sclerostin was measured by ELISA (within-assay CV of 5.5%, between-assays CV of 5.8%; TECOmedical, Sissach, Switzerland). Amino-terminal collagen cross-links (NTX) was measured by ELISA (within-assay CV of 4.6%, between-assays CV of 6.9%; Wampole Laboratories, Princeton, NJ). Bone alkaline phosphatase (BAP) was measured by ELISA (within-assay CV of 5.0%, between-assays CV of 5.9%; Quidel, San Diego, CA), and Ca, inorganic phosphorous (Pi), albumin, and creatinine (Cr) were measured using Roche COBAS MIRA Clinical Analyzer (Roche Diagnostic, Indianapolis, IN).
Data analysis
SAS version 9.2 (SAS, Cary, NC) was used to perform all statistical analyses. The distributions of variables were examined, and skewed data were transformed to produce normal distributions. Means for all variables were compared between the bariatric surgery and control groups using two-sample t tests. Inspection of the distributions of the variables indicated that the two groups overlapped. Therefore, Pearson correlations were performed on the total 40 subjects to assess relationships among variables. The correlation plots were inspected for potential bias from postmenopausal status. Multiple regression analysis was performed to explore the contributions of serum leptin and other selected variables including postmenopausal status to serum concentrations of PTH, 25D, BAP, NTX, sclerostin, and FGF23. Variables selected for inclusion in the multiple regression analyses were based on physiologically expected outcomes. The following variables were included for: 1) leptin, Ca, 1,25D, 25D, FGF23, and Pi for PTH; 2) leptin, Ca, PTH, 25D, FGF23, scleros- (Table 1) The bariatric surgery subjects were shorter (P ϭ 0.012) and heavier (P Ͻ 0.0001) than the controls but did not differ in age. All the bariatric patients were severely obese (BMI Ͼ35 kg/m 2 ), and of the controls, six were obese (BMI Ͼ30 kg/m 2 ) and four were overweight (BMI ϭ 25.0 -29.9 kg/m 2 ). Leptin (P Ͻ 0.0001), PTH (P Ͻ 0.0001), FGF23 (P ϭ 0.0002), and BAP (P Ͻ 0.0001) were higher, and 1,25D (P ϭ 0.049) was lower in the bariatric surgery group. There was no significant difference in sclerostin, 25D, NTX, Ca, Pi, or Cr between groups. Postmenopausal status did not affect any of the biochemical variables except NTX, which was higher in the postmenopausal patients.
Results
Anthropometric and biochemical variables
Pearson correlations (Table 2)
In the bariatric surgery and control groups combined (n ϭ 40), BMI correlated positively with leptin (P Ͻ 0.0001), PTH (P ϭ 0.036), FGF23 (P ϭ 0.0004), and BAP (P ϭ 0.02) and negatively with 1,25D (P ϭ 0.018) and 25D (P ϭ 0.04). Leptin correlated positively with PTH (P ϭ 0.003), FGF23 (P ϭ 0.002), and BAP (P ϭ 0.002) (Figure 1 , A-C) and negatively with 25D (P ϭ 0.03). PTH correlated negatively with Ca (P ϭ 0.001) and positively with BAP (P ϭ 0.004). 1,25D was negatively correlated with FGF23 (P ϭ 0.03) (Fig. 2) and positively correlated with 25D (P ϭ 0.0003). Sclerostin did not relate to any of the variables measured. BAP correlated positively with NTX (P ϭ 0.001) and negatively with 25D (P ϭ 0.04). Age was positively related to NTX (P ϭ 0.009) and Pi (P ϭ 0.03). Postmenopausal status did not affect the correlations judged by inspection of the correlation plots and significance of the r values. (Table 3) The strongest predictor for PTH was leptin (partial R 2 ϭ 0.21; P Ͻ 0.002), followed by Ca (partial R 2 ϭ 0.18; P ϭ 0.002). Correlation slope was positive for leptin and negative for Ca. The strongest predictor for 1,25D was 25D (partial R 2 ϭ 0.29; P ϭ 0.0002), followed by FGF23 (partial R 2 ϭ 0.07; P ϭ 0.04) and Pi (partial R 2 ϭ 0.06; P ϭ 0.06). The correlation slope for 25D was positive, whereas those for FGF23 and Pi were negative. The strongest predictor for FGF23 was leptin (partial R 2 ϭ 0.22; P ϭ 0.009) followed by 1,25D (partial R 2 ϭ 0.05; P ϭ 0.12). The correlation slope was positive for leptin and negative for 1,25D. The strongest predictor for BAP was leptin (partial R 2 ϭ 0.23; P ϭ 0.002) followed by PTH (partial R 2 ϭ
Multiple regression models
FIG. 1.
The relationship between serum leptin and serum PTH (R 2 ϭ 0.21; P Ͻ 0.01) (A), serum 1,25D (R 2 ϭ 0.08; P ϭ 0.07) (B), and serum FGF23 (R 2 ϭ 0.22; P Ͻ 0.01) (C) in bariatric patients (F) and control women (E) (n ϭ 40).
FIG. 2.
The relationship between serum FGF23 and serum 1,25D (R 2 ϭ 0.12; P ϭ 0.03) in bariatric patients (F) and control women (E) (n ϭ 40).
0.06; P ϭ 0.08) and Ca (partial R 2 ϭ 0.10; P ϭ 0.02). The three correlation slopes were positive.
The strongest predictor for sclerostin was PTH (partial R 2 ϭ 0.11; P ϭ 0.03) followed by leptin (partial R 2 ϭ 0.09; P ϭ 0.007). The correlation was negative for PTH and positive for leptin.
Menopausal status was not a significant predictor in the multiple regression models, and excluding postmenopausal did not affect the results of the original analysis.
Discussion
This case control study of patients scheduled for bariatric surgery demonstrated that obesity is associated with abnormal serum levels of PTH, 1,25D, and FGF23, the primary hormones regulating calcium and phosphate homeostasis. Although abnormalities in serum PTH (27) (28) (29) (30) and 1,25D (27, 46) are well described, this study is one of the first to describe abnormal serum levels of FGF23, the main hormone regulating phosphate homeostasis. Furthermore, the data suggest that the changes in serum levels of these mineral-regulating hormones are, in part, due to effects of the levels of serum leptin, the adipocyte hormone that best reflects total body fat in subjects with simple obesity (13) . In the current study, serum leptin correlated with BMI with an r value of over 0.9.
Increased serum PTH concentrations are well described in obesity (28 -30) . Many researchers have attributed these increases to secondary hyperparathyroidism in response to low serum levels of 25D, which is a common finding in obesity (27, 32) . However, we (30) and others (35) have shown that vitamin D insufficiency does not explain the hyperparathyroidism of obesity, and the current study corroborates this. Although the 25D levels in this study ranged from 7.6 -31.1 ng/ml in the bariatric patients and the control subjects combined, there was no significant relationship between PTH and 25D. Nor was the increase in PTH due to decreased renal function, a common accompaniment of obesity (47), because Cr was in the normal range in both groups, and there was no relationship between PTH and Cr. On the other hand, there was a positive significant relationship between PTH and leptin over a leptin range of 3.3-109.3 ng/ml. Multiple regression analysis demonstrated that serum leptin was the highest predictive serum variable for PTH with Ca providing only a small negative prediction. If the association between leptin and PTH is causative, it implies that leptin directly affects PTH secretion either through endocrine or paracrine mechanisms. There are no direct studies to support or refute either of these mechanisms. However, it is perhaps relevant that obese patients with primary hyperparathyroidism have higher serum PTH and higher parathyroid tumor weight than nonobese patients (48, 49), suggesting that leptin acts to increase parathyroid cell mass. Thus, leptin may be acting as a mitogene (50) regulating parathyroid cell mass through paracrine mechanisms. There was no observable effect of PTH on Ca, Pi, or 1,25D, suggesting that either the PTH changes may not be large enough to measure a response in these target variables or that other regulatory factors dominate. Despite this, as discussed below, PTH predicted bone formation marker, BAP, indicating its role in bone turnover.
In this study, FGF23 was higher in the bariatric patients than the controls and positively correlated with leptin. Leptin directly stimulates FGF23 synthesis in bone cells in the ob/ob mouse (51), suggesting that leptin may be an endocrine or paracrine regulator of FGF23 production in humans. A major action of FGF23 is to decrease renal tubular reabsorption of Pi (52), and thus a decrease in Pi might have been expected. However, this was not seen; Pi did not differ between bariatric and control subjects, and there was no relationship between Pi and FGF23. Renal tubular reabsorption of Pi was not directly measured in this study, and an effect of an increase in FGF23 on renal Pi transport cannot be excluded. Serum 1,25D has been reported to be both high (27) and low (39) in obesity. The explanation for this lack of consistency is not clear. It may lie in variation in the size and heterogeneity of the samples of patients reported and in the technique of measuring 1,25D by immunoassay, which is not completely specific and measures other vitamin D metabolites in serum. In this study 1,25D was lower in the bariatric patients than in controls. It is interesting that 1,25D was negatively related to FGF23 in light of increasing evidence that FGF23 is a major down-regulator of renal 1,25D secretion (43, 52). In this study, there was no relationship between 1,25D and PTH, suggesting that in obesity, FGF23 suppression of 1,25D secretion overrides any stimulatory effect of PTH. The opposing effect of FGF23 and PTH on 1,25D secretion may also be part of the explanation for the variation in reported values of 1,25D in obesity. As we and others have shown previously (30, 53) , bone turnover markers are increased in obesity. In this study, there was the expected relationship between a formation marker, BAP, and a bone resorption marker, NTX. However, the most significant difference between bariatric surgery patients and controls was found in the bone formation marker BAP. In multiple regression analysis, both PTH and leptin positively predicted BAP, suggesting a direct effect of leptin on the osteoblast.
Sclerostin, produced by osteocytes, is a major regulator of bone mass, and its production is down-regulated by PTH (37). Patients with primary hyperparathyroidism have lower serum sclerostin levels than euparathyroid control subjects, and there is an inverse relationship between serum PTH and sclerostin levels (54) In this study, although there was no difference in serum sclerostin between bariatric surgery subjects and controls, multiple regression analysis indicated that PTH negatively predicted serum sclerostin concentrations, suggesting that the PTHsclerostin relationship may be one of the factors linking high bone mass with high fat mass.
Weaknesses of the study are that it involved relatively small sample sizes and studied only white women. Future studies in men and subjects of different races will be needed to show whether these results can be replicated and applied more generally. The study was cross-sectional, and detailed longitudinal studies before and after bariatric surgery will be required to establish the factors that trigger the abnormalities in the mineralregulating hormones, and how these change with reductions in fat mass. The study was not matched for postmenopausal status. Although bariatric patients and control subjects were matched for age, seven of the bariatric patients were postmenopausal and four of these were on sex steroid replacement therapy. However, serum NTX was the only biochemical variable that was influenced by postmenopausal status. The strength to the study is that it is a case control study in subjects that overlap and span a wide range of BMI. The study corroborates our recent study showing that hyperparathyroidism in obesity is not vitamin D or renal function dependent (30) . Furthermore, it corroborates our hypothesis that serum leptin is one of the factors directly involved in the mechanisms leading to changes in the mineral-regulating hormones.
In summary, this case control study of patients selected for bariatric surgery demonstrates that they have increased PTH and FGF23 and that these changes directly relate to changes in leptin. The results suggest that leptin has an endocrine or paracrine effect on PTH and FGF23 production. Serum 1,25D was reduced and appeared to be the result of increased FGF23. 
